Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18799714 | RELAXIN-2 FUSION PROTEINS | August 2024 | February 2025 | Allow | 6 | 0 | 1 | No | No |
| 18606135 | ANTIBODIES AND METHODS OF USE | March 2024 | September 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18589804 | Monoclonal Antibody Against Canine Fibroblast Activation Protein that Cross-Reacts with Mouse and Human Fibroblast Activation Protein (FAP) | February 2024 | February 2026 | Abandon | 24 | 2 | 1 | No | No |
| 18435440 | FIBROBLAST GROWTH FACTOR-21-FC FUSION PROTEINS | February 2024 | September 2025 | Allow | 19 | 1 | 1 | No | No |
| 18409969 | VEGF-BINDING MOLECULES | January 2024 | July 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18525130 | C-TERMINAL ANTI-SCLEROSTIN ANTIBODY VARIANTS | November 2023 | December 2025 | Allow | 25 | 1 | 0 | No | No |
| 18507579 | IL-1 Receptor Accessory Protein-Inhibiting Antibodies and Antigen-Binding Fragments Thereof | November 2023 | May 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18482487 | Modified Relaxin Polypeptides and Their Uses | October 2023 | September 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18480071 | ANTIBODY TO INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R) AND RELATED COMPOSITIONS AND USES | October 2023 | January 2026 | Allow | 27 | 1 | 1 | Yes | No |
| 18453182 | Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Metabolic Disorders and Diseases | August 2023 | September 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18366447 | METHODS FOR INCREASING SERUM CONCENTRATION OF PHOSPHOROUS AND/OR 1,25-HYDROXY VITAMIN D | August 2023 | March 2025 | Allow | 19 | 1 | 0 | No | No |
| 18365969 | Leptin Antibodies and Method of Reducing Leptin | August 2023 | March 2024 | Allow | 7 | 0 | 0 | No | No |
| 18357632 | Methods to improve glucose tolerance in a subject by administering an antibody that binds to extracellular human metallothionein 1A (MT1A) | July 2023 | November 2025 | Allow | 28 | 1 | 1 | No | No |
| 18335440 | DNA-REPLICATION ASSOCIATED (REP) PROTEIN ANTIBODY | June 2023 | September 2025 | Allow | 28 | 2 | 1 | No | No |
| 18326510 | MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF | May 2023 | April 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18317869 | MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO MATRILIN 3 AND THEIR USE | May 2023 | August 2024 | Abandon | 15 | 1 | 1 | No | No |
| 18313282 | FUSION PROTEIN INCLUDING GIP AND FGF21 AND COMPOSITIONS THEREOF | May 2023 | April 2025 | Allow | 23 | 2 | 1 | No | No |
| 18142070 | ANTI-ADRENOMEDULLIN ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS THEREOF | May 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
| 18297154 | METHOD OF TREATING VASCULAR EYE AND RETINAL DISEASES BY ADMINISTRATION OF ANTI-NEUROPILIN 1A ANTIBODIES | April 2023 | October 2025 | Allow | 30 | 1 | 0 | No | No |
| 18194276 | ANTIBODIES AND METHODS OF USE | March 2023 | June 2024 | Abandon | 15 | 0 | 1 | No | No |
| 18043894 | Compositions and Methods For Inhibiting FGF23 Activity | March 2023 | September 2025 | Abandon | 30 | 0 | 0 | No | No |
| 18176172 | MUTANT FIBROBLAST GROWTH FACTOR 21 (FGF21) POLYPEPTIDES | February 2023 | October 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 18166996 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA BY ADMINISTRATION OF A BISPECIFIC ANTIBODY TO VEGF AND ANG-2 | February 2023 | September 2025 | Allow | 31 | 2 | 1 | No | No |
| 18158713 | Methods of Using Compositions Comprising Variants of FGF19 Polypeptides for Treating Bile Acid Diarrhea (BAD) and Progressive Familial Intrahepatic Cholestasis (PFIC) in a Subject | January 2023 | December 2025 | Abandon | 34 | 3 | 1 | No | No |
| 18153643 | POLYNUCLEOTIDES ENCODING HUMAN BETA KLOTHO ANTIBODIES OR BINDING FRAGMENTS THEREOF AND METHODS OF USE THEREOF | January 2023 | April 2025 | Allow | 27 | 1 | 0 | Yes | No |
| 18152439 | METHODS OF REDUCING OR HINDERING DEVELOPMENT OF ISCHEMIA-REPERFUSION INJURY DUE TO KIDNEY TRANSPLANTATION WITH AN ANTIBODY THAT INHIBITS GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) SIGNALING | January 2023 | November 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 18013462 | GLP-1R AGONIST / FGF21 FUSION PROTEINS | December 2022 | October 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 18066156 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | December 2022 | March 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18063550 | BISPECIFIC ANTIBODY AGAINST ALPHA-SYN/IGF1R AND USE THEREOF | December 2022 | October 2024 | Abandon | 23 | 0 | 1 | No | No |
| 18053857 | METHOD OF TREATING OR PREVENTING LIVER CONDITIONS | November 2022 | July 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18045964 | Anti-Angiopoietin-2 Antibodies that Induce Tie2 Activation | October 2022 | February 2025 | Allow | 29 | 3 | 1 | No | No |
| 17936073 | ANTIBODY THAT BINDS TO VEGF AND PDGF-B | September 2022 | February 2026 | Allow | 41 | 0 | 1 | No | No |
| 17935788 | METHODS FOR TREATING HYPERTENSION USING AN ANTI-BMP10 MONOCLONAL ANTIBODY OR FRAGMENT THEREOF | September 2022 | December 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17934585 | C-TERMINAL ANTI-SCLEROSTIN ANTIBODY VARIANTS | September 2022 | August 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 17906627 | New anti-VEGFC antibodies and uses thereof | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17932950 | METHOD OF TREATING GLOMERULONEPHRITIS BY ADMINISTERING AN ANTIBODY WHICH BINDS AND NEUTRALIZES HUMAN TGF-BETA1, TGF-BETA2 AND TGF-BETA3 | September 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17929254 | KIT COMPRISING ANTIBODY BINDING ACROLEIN-PROTEIN CONJUGATE FOR DIAGNOSING NEPHROPATHY | September 2022 | August 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17801066 | AFFINITY LIGAND FOR THE SOLUBLE PART OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (sFGFR3) | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17819766 | FGF ANALOG | August 2022 | May 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17814608 | Therapeutic Use of Modified Relaxin Polypeptides Comprising a Non-Naturally Encoded Amino Acid | July 2022 | May 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17871953 | ORAL DELIVERY COMPOSITIONS FOR OBSITY MANAGMENT | July 2022 | January 2025 | Abandon | 30 | 1 | 2 | Yes | No |
| 17812412 | METHODS OF TREATING GASTROINTESTINAL DISEASES CHARACTERIZED BY INFLAMMATORY CELLS | July 2022 | October 2023 | Allow | 16 | 1 | 1 | No | No |
| 17844812 | VEGF-BINDING MOLECULES | June 2022 | January 2024 | Abandon | 19 | 1 | 1 | No | No |
| 17756772 | ANTIBODY AGAINST SARS-COV-2 | June 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17779210 | FGF2 POLYPEPTIDE WITH IMPROVED TEMPERATURE STABILITY AND PROTEASE RESISTANCE AND USE THEREOF | May 2022 | July 2024 | Allow | 26 | 0 | 0 | No | No |
| 17664349 | METHODS OF USE FOR IL-1 RECEPTOR ACCESSORY PROTEIN INHIBITORS | May 2022 | January 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17778512 | METHODS OF CANCER TREATMENT WITH ANTI-OX40 ANTIBODY IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS | May 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17774755 | INHIBITION OF THE VE-PTP PHOSPHATASE PROTECTS THE KIDNEY FROM ISCHEMIA-REPERFUSION INJURY | May 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17774250 | ANTIBODY SPECIFICALLY RECOGNIZING ITIH1, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR IMPROVING INSULIN RESISTANCE IN DISEASES ACCOMPANIED BY IMPAIRED GLUCOSE TOLERANCE | May 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17769826 | MEASUREMENT OF BEVACIZUMAB-INSENSITIVE VASCULAR ENDOTHELIAL GROWTH FACTOR-A | April 2022 | March 2026 | Allow | 47 | 3 | 1 | Yes | No |
| 17721569 | TREATMENT OF FIBROSIS, CARDIOVASCULAR DISEASE AND HEART FAILURE WITH MODIFIED RELAXIN POLYPEPTIDES | April 2022 | May 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17716507 | METHODS AND COMPOSITIONS FOR OX40 ACTIVATION IN TREATMENT OF CANINE CANCER | April 2022 | March 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17706543 | ANTI-SEMAPHORIN 3A ANTIBODIES | March 2022 | April 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17704170 | Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF Fab | March 2022 | November 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17693057 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY | March 2022 | August 2024 | Allow | 30 | 2 | 1 | No | No |
| 17640083 | ANTI-VEGF SINGLE-DOMAIN ANTIBODY AND USE THEREOF | March 2022 | March 2026 | Allow | 48 | 2 | 1 | Yes | No |
| 17685658 | Modified Relaxin Polypeptides and Their Uses | March 2022 | May 2023 | Allow | 15 | 1 | 0 | No | No |
| 17583930 | ANTI-PDGF-B ANTIBODIES AND PHARMACEUTICAL COMPOSITION THEREOF | January 2022 | February 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17629277 | FGF21 FC FUSION PROTEIN, GLP-1 FC FUSION PROTEIN, AND COMBINATION THERAPEUTIC AGENT COMPRISING SAME AND USE THEREOF | January 2022 | May 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17578424 | Humanized anti-VEGF antibody Fab fragment | January 2022 | June 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17573238 | METHODS OF TREATING KIDNEY FAILURE, AND/OR IMPROVING OR STABLIZING RENAL FUNCTION USING MODIFIED RELAXIN POLYPEPTIDES | January 2022 | May 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17562732 | METHODS OF USING COMPOSITIONS COMPRISING VARIANTS OF FGF19 POLYPEPTIDES FOR REDUCING BILE ACID SYNTHESIS IN A SUBJECT | December 2021 | February 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17559050 | Application of FGF21 in preparation of medicine for treating colorectal cancer | December 2021 | March 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17555633 | Nucleic Acids Encoding Modified FGF-21 Polypeptides, Vectors and Cells Containing, and Use Thereof | December 2021 | October 2024 | Allow | 34 | 2 | 1 | No | No |
| 17616799 | BISPECIFIC ANTIBODY AGAINST Alpha-SYNUCLEIN AND INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R) AND COMPOSITIONS AND USES THEREOF | December 2021 | March 2025 | Allow | 39 | 1 | 1 | No | No |
| 17541411 | FGF21 VARIANTS | December 2021 | March 2025 | Abandon | 39 | 3 | 1 | Yes | Yes |
| 17614845 | METHODS OF TREATING SENSORINEURAL HEARING LOSS USING FIBROBLAST GROWTH FACTOR 2 (FGF2) | November 2021 | April 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17532397 | ANTI-IGFBP-3R ANTIBODIES AND METHODS OF TREATING AN IGFBP-3R EXPRESSING CANCER | November 2021 | June 2023 | Allow | 18 | 0 | 1 | No | No |
| 17525738 | METHODS FOR TREATING TUMOR-INDUCED OSTEOMALACIA | November 2021 | May 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17496597 | ANTI-NGF ANTIBODIES AND METHODS OF USE THEREOF | October 2021 | January 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17442012 | MARKER COMPOSITION FOR DIAGNOSING CANCER OR PREDICTING PROGNOSIS ON BASIS OF EXOSOME OVEREXPRESSING TUBA1C PROTEIN | September 2021 | August 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17478628 | DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | September 2021 | October 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17478600 | LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | September 2021 | November 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17410307 | Fibroblast Growth Factor-21-Fc Fusion Proteins | August 2021 | November 2023 | Allow | 26 | 1 | 0 | No | No |
| 17403078 | BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE | August 2021 | August 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17310377 | FIBROBLAST GROWTH FACTOR 21 VARIANT, AND FUSION PROTEIN AND USE THEREOF | July 2021 | July 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17368108 | ANTI-DINITOLMIDE MONOCLONAL ANTIBODIES AND HYBRIDOMA CELL STRAIN THAT SECRETES THEM | July 2021 | March 2025 | Allow | 44 | 2 | 1 | No | No |
| 17365183 | FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides | July 2021 | March 2024 | Allow | 32 | 2 | 1 | No | No |
| 17357444 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS USING FGF21 MUTANTS | June 2021 | July 2023 | Allow | 25 | 2 | 0 | No | No |
| 17356070 | Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Metabolic Disorders and Diseases | June 2021 | September 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17355002 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEPTIDE VARIANTS AND METHODS OF USE THEREOF | June 2021 | May 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17350273 | ANTI-VEGF ANTIBODY WHICH INHIBITS BINDING OF VEGF to VEGF-R1 | June 2021 | November 2024 | Allow | 41 | 0 | 0 | No | No |
| 17341990 | ANTIBODIES AND METHODS OF USE | June 2021 | April 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17341212 | CANINIZED ANTI-TGFBETA ANTIBODIES | June 2021 | November 2025 | Allow | 54 | 3 | 1 | Yes | No |
| 17299383 | ANTI-IGF-I RECEPTOR HUMANIZED ANTIBODY | June 2021 | October 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17332062 | MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF | May 2021 | March 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17290164 | BIOMARKERS OF SUBCLINICAL ATHEROSCLEROSIS | April 2021 | April 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17242667 | BISPECIFIC ANTI-VEGF/ANG2 ANTIBODY FORMULATION | April 2021 | August 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17229271 | HIGH-AFFINITY ANTI-VEGF ANTIBODY KLHa505 | April 2021 | September 2023 | Allow | 29 | 0 | 1 | No | No |
| 17283794 | ENGINEERED FIBROBLAST GROWTH FACTOR 1 VARIANTS WITH INCREASED PROTEOLYTIC STABILITY | April 2021 | March 2026 | Allow | 59 | 4 | 1 | Yes | No |
| 17283913 | ENGINEERED FIBROBLAST GROWTH FACTOR VARIANTS COMBINED WITH ENGINEERED HEPATOCYTE GROWTH FACTOR VARIANTS FOR TREATING CORNEAL NEOVASCULARIZATION | April 2021 | March 2026 | Abandon | 59 | 2 | 1 | Yes | No |
| 17217953 | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | March 2021 | July 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17280602 | METHOD AND KIT FOR QUANTIFYING LIVER-TYPE FATTY ACID BINDING PROTEIN, METHOD AND KIT FOR TESTING FOR KIDNEY DISEASES, AND COMPANION DIAGNOSTIC DRUG | March 2021 | October 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17204311 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED | March 2021 | April 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17276611 | METHOD OF TREATING WASTING DISORDERS | March 2021 | December 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17199732 | Nucleic Acids Encoding Humanized Anti-NGF Antibodies | March 2021 | October 2025 | Allow | 56 | 3 | 1 | No | No |
| 17197358 | Humanized Anti-NGF Antibodies and Methods of Treating Pain Thereof | March 2021 | May 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17195827 | Use of IL-1 beta Binding Antibodies | March 2021 | August 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17196135 | Nucleic Acids Encoding a Canine Antibody Which Binds Nerve Growth Factor and Vectors and Host Cells Thereof | March 2021 | March 2024 | Allow | 36 | 1 | 1 | No | No |
| 17196592 | METHODS OF SUPPORTING WEIGHT MAINTENANCE BY DECREASING THE ACTIVITY OF FAM46A | March 2021 | October 2024 | Abandon | 43 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SAOUD, CHRISTINE J.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SAOUD, CHRISTINE J works in Art Unit 1645 and has examined 244 patent applications in our dataset. With an allowance rate of 81.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner SAOUD, CHRISTINE J's allowance rate of 81.1% places them in the 52% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SAOUD, CHRISTINE J receive 1.78 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SAOUD, CHRISTINE J is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +9.6% benefit to allowance rate for applications examined by SAOUD, CHRISTINE J. This interview benefit is in the 42% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 33.1% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 60.6% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 72.7% of appeals filed. This is in the 61% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 78.3% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 17.6% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.2% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.